Clear context. No promises.
Information services for people seeking grounded context on ibogaine-related approaches to alcohol use disorder: guides, comparisons, research summaries, and practical questions to carry forward.
Clear Ember is an independent resource. The starting point is the broader ibogaine and alcohol use disorder context, then a closer look at what is known, what remains uncertain, and what safety questions matter. Our purpose and principles explain why the work favors plain language, evidence before hype, and direct acknowledgment of limits.
What we make available
These are informational offerings, not clinical services. They are designed to help readers separate claims from evidence, identify unanswered questions, and understand why medical and legal context cannot be skipped.
Guides establish shared language around ibogaine, alcohol use disorder, and the questions that can be obscured by marketing. For foundational terminology, the basic treatment overview can help clarify what people may mean when they use ibogaine-related terms.
Research summaries distinguish early signals, study limits, and claims that exceed available evidence. Ibogaine remains a Schedule I controlled substance in the United States, a regulatory fact that is essential context for any discussion of access or research.
Comparison material helps readers assess how programs describe screening, monitoring, aftercare, and uncertainty without treating those descriptions as endorsements. Context around treatment centers in Mexico belongs alongside questions about standards, claims, and individual risk.
Short definitions and focused answers help make unfamiliar concepts easier to evaluate. The ibogaine HCl reference material is one point of orientation for readers encountering formulation language that may otherwise be unclear.
A decision framework
Alcohol use disorder is a recognized medical condition, not a simple failure of will. The National Institute on Alcohol Abuse and Alcoholism describes alcohol use disorder in terms of impaired control, consequences, and other diagnostic features; no single informational source can determine what is right for an individual.
Separate a stated claim from proof. A claim about alcohol use, withdrawal, craving, or recovery should be read alongside the kind of evidence offered and the uncertainty left unaddressed.
Look for study design, participant numbers, follow-up, outcomes, and limitations. The evidence and trials material offers a place to frame those questions without presenting research as a guarantee.
Risk questions are central, particularly where heart rhythm, medication interactions, withdrawal, and monitoring may be relevant. A separate safety reference can also place discussions of ibogaine treatment in Texas in a wider legal and practical context.
How to use the resource
Information cannot replace individual medical assessment. It can, however, make the next question more specific and make uncertainty easier to recognize.
Identify what ibogaine-related language is actually describing before comparing claims, options, or sources.
Ask whether a statement is based on preclinical work, observations, controlled research, or personal accounts.
Review the safety and consideration questions before treating any claim as a practical recommendation.
Ibogaine is an indole alkaloid associated with the iboga plant, but that description alone does not establish a safe or effective approach for alcohol use disorder.
Common questions
No. Clear Ember is an independent information resource, not a clinic, medical provider, or licensed treatment center. It offers context on ibogaine-related approaches to alcohol use disorder and does not provide treatment, diagnosis, or individualized medical guidance.
No. Guides can describe evidence, regulation, terminology, and questions to consider, but they cannot account for an individual’s health history, medications, alcohol use, or withdrawal risk. Those limits are central to the overview of what ibogaine is.
Adjacent claims can shape expectations, so they need context rather than promotion. For example, material concerning ibogaine treatment for Parkinson’s should be understood as separate from questions about alcohol use disorder and not as evidence for it.
Clear Ember’s mission is to make the evolving evidence, risks, regulation, and unanswered questions easier to see. The goal is not to direct a treatment decision, but to support clearer thinking around a complex subject.